Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 13 years~* Signed written informed consent~* Clear clinical and laboratory diagnosis of HAE with baseline plasma level of functional C1INH of less than 50% of normal~* Willingness and ability to comply with all protocol procedures~* Clinical symptoms of an eligible HAE attack with onset less than 5 hours before the time of initial evaluation~Exclusion Criteria:~* Medical history of allergy to rabbits or rabbit-derived products (including rhC1INH), or positive anti-rabbit dander IgE test (cut off \>0.35 kU/L; ImmunoCap® assay; Phadia or equivalent).~* A diagnosis of acquired C1INH deficiency (AAE)~* Pregnancy, or breastfeeding, or current intention to become pregnant~* Treatment with any investigational drug in the past 30 days~* Known or suspected addiction to drug and/or alcohol abuse~* Suspicion for an alternate explanation of the symptoms other than acute HAE attack

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhC1INH (Type: EXPERIMENTAL): None
- Placebo (Saline) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).